Literature DB >> 15804279

Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Graham Packham1, Freda K Stevenson.   

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy in the Western world and exists as subtypes with very different clinical courses. CLL is generally described as a disease of failed apoptosis. Apoptosis resistance may stem from a combination of microenvironmental survival signals as well as from intrinsic alterations in the apoptotic machinery within the CLL cell. The molecular mechanism involved in controlling apoptosis in CLL is complex and is influenced by many factors, including Bcl-2 family proteins, which are critical regulators of cell death. Here we review the significance of apoptosis dysregulation in CLL, focusing on the role of Bcl-2 and related Bcl-2 family proteins, such as Bax and Mcl-1. The differential properties of the newly described subsets of CLL are also highlighted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804279      PMCID: PMC1782118          DOI: 10.1111/j.1365-2567.2005.02117.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  69 in total

Review 1.  Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector.

Authors:  J M Adams; A W Harris; A Strasser; S Ogilvy; S Cory
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

2.  Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia.

Authors:  F Morabito; M Mangiola; B Oliva; C Stelitano; V Callea; S Deaglio; P Iacopino; M Brugiatelli; F Malavasi
Journal:  Leuk Res       Date:  2001-11       Impact factor: 3.156

3.  ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.

Authors:  Liguang Chen; John Apgar; Lang Huynh; Frank Dicker; Teresa Giago-McGahan; Laura Rassenti; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

4.  Mcl-1 deficiency results in peri-implantation embryonic lethality.

Authors:  J L Rinkenberger; S Horning; B Klocke; K Roth; S J Korsmeyer
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

5.  Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia.

Authors:  C Pepper; A Thomas; T Hoy; F Cotter; P Bentley
Journal:  Br J Haematol       Date:  1999-12       Impact factor: 6.998

6.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

Authors:  U Klein; Y Tu; G A Stolovitzky; M Mattioli; G Cattoretti; H Husson; A Freedman; G Inghirami; L Cro; L Baldini; A Neri; A Califano; R Dalla-Favera
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

7.  Survival of leukemic B cells promoted by engagement of the antigen receptor.

Authors:  A Bernal; R D Pastore; Z Asgary; S A Keller; E Cesarman; H C Liou; E J Schattner
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

8.  Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells.

Authors:  C Pepper; K Hooper; A Thomas; T Hoy; P Bentley
Journal:  Leuk Lymphoma       Date:  2001-07

9.  In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.

Authors:  B Bellosillo; N Villamor; D Colomer; G Pons; E Montserrat; J Gil
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  47 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

2.  Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.

Authors:  Ting Song; Gaobo Chai; Yubo Liu; Xiaoyan Yu; Ziqian Wang; Zhichao Zhang
Journal:  Br J Pharmacol       Date:  2016-01-16       Impact factor: 8.739

3.  Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice.

Authors:  Stefano Bruscoli; Michele Biagioli; Daniele Sorcini; Tiziana Frammartino; Monica Cimino; Paolo Sportoletti; Emanuela Mazzon; Oxana Bereshchenko; Carlo Riccardi
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

4.  Increased stability of Bcl-2 in HSP70-mediated protection against apoptosis induced by oxidative stress.

Authors:  Bimei Jiang; Pengfei Liang; Gonghua Deng; Zizhi Tu; Meidong Liu; Xianzhong Xiao
Journal:  Cell Stress Chaperones       Date:  2010-10-03       Impact factor: 3.667

5.  Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.

Authors:  Duonan Yu; Diana Cozma; Andrea Park; Andrei Thomas-Tikhonenko
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

6.  Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Authors:  V M Patel; K Balakrishnan; M Douglas; T Tibbitts; E Y Xu; J L Kutok; M Ayers; A Sarkar; R Guerrieri; W G Wierda; S O'Brien; N Jain; H M Stern; V Gandhi
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

7.  CASP3 protein expression by flow cytometry in Down's syndrome subjects.

Authors:  Michele Salemi; Rosita A Condorelli; Corrado Romano; Barone Concetta; Carmelo Romano; Maria Grazia Salluzzo; Paolo Bosco; Aldo E Calogero
Journal:  Hum Cell       Date:  2013-12-13       Impact factor: 4.174

8.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

9.  Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.

Authors:  M Russo; C Spagnuolo; S Volpe; A Mupo; I Tedesco; G-L Russo
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

10.  Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.

Authors:  Jianguo Zhuang; Stephen F Hawkins; Mark A Glenn; Ke Lin; Gillian G Johnson; Anthony Carter; John C Cawley; Andrew R Pettitt
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.